Published November 2012 | Pages 246
Analyzing the Hepatitis C Market Landscape
After more than a decade of limited treatment options, the hepatitis C (HCV) market is on the cusp of a treatment revolution. In 2011, protease inhibitors-Incivek (telaprevir; Vertex) and Victrelis (boceprevir; Merck)-became the first new drugs approved in the disease in over a decade; however after a bright start sales have plateaued as treatment is held back in less severe populations. Key opinion leaders cite this ‘warehousing’ effect is due to the anticipated arrival of the more convenient, efficacious and safer therapies. Pipeline combinations led by Gilead, Abbott, Bristol-Myers Squibb and Boehringer Ingelheim all have favourable clinical results and notably are not used in conjunction with pegylated-interferon alpha, a key component in the current standard of care but associated with tolerability issues. The battle to be the first will be intense as availability of a non-interferon regimen will transform this potentially lucrative market.
‘Therapy Trends: Hepatitis C’ is compiled from exclusive, in-depth interviews with the world’s leading KOLs in HCV. It identifies and analyses the major factors, advances and trends currently influencing the HCV treatment landscape. The report focuses on late-stage pipeline products, and how these could modify future HCV management.
FirstWord selected KOLs to participate in this Therapy Trends research based on their level of engagement and influence within the HCV pharmaceutical industry, and their scientific standing. Our unique KOL scoring system identifies those thought-leaders with the greatest insight into how HCV clinical research will shape the future market.
Critical Questions Answered
Understand the Global Hepatitis C Market
The hepatitis C (HCV) market is expected to become one of the fastest growing markets in Pharma over the next decade given a sizable 170 million patient population, a significant unmet need and rapid advancements in the clinic. The management of this infectious disease is on the verge of a revolution that will bring considerable changes to the treatment algorithm. KOLs from North America and Europe provide answers to the critical questions regarding the global HCV market, including:
- What do KOLs make of the Incivek and Victrelis and their impact on treatment?
- What are the current unmet needs and major challenges in HCV treatment?
- What are the most promising late-stage classes in development?
- Which therapy are KOLs eagerly awaiting?
- How will the nucleotide inhibitors, non-nucs, and NS5A inhibitors be positioned in the HCV market?
- How do the second generation protease inhibitors differ from their first-generation cousins?
- In what ways could eventual biomarkers improve future HCV disease management?
- How will treatment of HCV look in the future?
- How do KOLs think the pricing environment will shape the uptake of new HCV treatments?
- What clinical research trends do KOLs predict for future HCV therapies?
Hepatitis C’s Panel of Key Opinion Leaders
FirstWord selected the KOLs for this Therapy Trends report based on their level of engagement and influence within the HCV pharmaceutical industry, and their scientific standing. The HCV KOL panel assembled for this Therapy Trends research is drawn from North American and European professionals:
Adult Viral Hepatitis Prevention Coordinator, Bureau of Epidemiology, Pennsylvania Department of Health, Harrisburg, PA, USA
Director of Hepatology, Medicine Service, Massachusetts General Hospital, MA, US
President and Medical Director at Alamo Medical Research, Texas, US
Head, Division of Gastroenterology and Hepatology, Scripps Clinic, CA, US
Chief Medical Officer at Alamo Medical Research Texas, US
Head of the Liver Institute of Virginia, Virginia, US
Department of Hépato-Gastroenterologie, Centre Hospitalier Universitaire de Nancy-Brabois, Vandoeuvre-lès-Nancy, France
Professor of Medicine at the University of Vienna, Vienna General Hospital, Wien, Austria
Professor at Hôpital Saint Eloi, Montpellier, France
Co-lead of HCV Research UK, MRC Virology Unit, Glasgow, ScotlandProfessor of Medicine and Chief of the Department of Medicine, J.W. Goethe University Hospital, Frankfurt, Germany
Qualitative Analysis Updated Within Days of Major Market Events
Stay a step ahead with Therapy Trends Event Assessments. Over the next 12 months, you will receive updated qualitative analysis every time a major market event breaks. Updates will be delivered straight into your inbox within days of each event’s occurrence.
Whether it’s a predicted product approval or an unexpected late stage failure, Therapy Trends has the resources and knowledge to keep you up to date with the latest market analysis.